Table 2.
Cox proportional-hazards model of mortality among stage 0–I bladder cancer patients with and without statins use.
| No. | Events (%) | Crude HR (95% CI) | p-Value | Adjusted † HR (95% CI) | p-Value | ||||
|---|---|---|---|---|---|---|---|---|---|
| All-cause mortality | |||||||||
| Statin (−) | 523 | 134 | (25.6) | 1.00 | (Ref.) | 1.00 | (Ref.) | ||
| Statin (+) | 313 | 60 | (19.2) | 0.72 | (0.53–0.97) | 0.0321 | 0.69 | (0.48–0.99) | 0.0433 |
| Bladder cancer-related mortality | |||||||||
| Statin (−) | 523 | 93 | (17.8) | 1.00 | (Ref.) | 1.00 | (Ref.) | ||
| Statin (+) | 313 | 27 | (8.6) | 0.46 | (0.30–0.70) | 0.0003 | 0.60 | (0.37–0.96) | 0.0335 |
† Adjusted for age, gender, cell type, BMI, CCI, TC, LDL-C. Abbreviations: BMI, body mass index; CCI, Charlson Comorbidity Index; CI, confidence interval; HR, hazard ratio; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol.